Pelthos Therapeutics Files Amended Ownership Report
Ticker: PTHS · Form: 4/A · Filed: 2026-04-01T17:43:41-04:00
Sentiment: neutral
Topics: insider-filing, ownership-change, amendment
TL;DR
Pelthos amended ownership filing from 2025. Check for insider moves.
AI Summary
Pelthos Therapeutics Inc. filed an amended Form 4/A on April 1, 2026, to report changes in beneficial ownership of securities. The filing pertains to a period of report ending July 2, 2025. Specific details regarding the nature of the changes and the individuals involved are not fully elaborated in the provided text.
Why It Matters
This filing provides updated information on who owns or controls significant amounts of Pelthos Therapeutics' stock, which can influence investor perception and trading activity.
Risk Assessment
Risk Level: low — The filing is an amendment to a previous ownership report and does not appear to contain new material financial information or significant strategic shifts.
Key Numbers
- 2026-04-01 — Filing Date (Date of the amended filing)
- 2025-07-02 — Period of Report (The period the ownership changes relate to)
Key Players & Entities
- Pelthos Therapeutics Inc. (company) — Issuer
- Aurinia Pharmaceuticals Inc. (company) — Mailing Address
- Greenleaf Peter (person) — Reporting Person
FAQ
What specific changes in beneficial ownership are being reported in this 4/A filing?
The provided text does not specify the exact nature of the changes in beneficial ownership, only that it is an amendment to a previous filing.
Who is the reporting person for this filing?
The reporting person is listed as Greenleaf Peter, with CIK 0001363683.
What is the CIK number for Pelthos Therapeutics Inc.?
The CIK number for Pelthos Therapeutics Inc. is 0001919246.
When was the original filing that this 4/A amends?
The filing date of the amended Form 4/A is April 1, 2026, but the original filing date is not specified in the provided text.
What is the business address of Pelthos Therapeutics Inc.?
The business address of Pelthos Therapeutics Inc. is 4020 Stirrup Creek Drive, Suite 110, Durham, NC 27703.
From the Filing
EDGAR Filing Documents for 0001919246-26-000043 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] SEC Accession No. 0001919246-26-000043 Filing Date 2026-04-01 Accepted 2026-04-01 17:43:41 Documents 2 Period of Report 2025-07-02 Document Format Files Seq Description Document Type Size 1 FORM 4/A wk-form4a_1775079819.html 4/A 1 FORM 4/A wk-form4a_1775079819.xml 4/A 4804 2 EX-24 pths-section16_poaxv5xgree.htm EX-24 6929 Complete submission text file 0001919246-26-000043.txt 13501 Mailing Address C/O AURINIA PHARMACEUTICALS INC. #140, 14315-118 AVENUE EDMONTON Alberta, Canada T5L 4S6 Business Address Greenleaf Peter ( Reporting ) CIK : 0001363683 (see all company filings) Type: 4/A | Act: 34 | File No.: 001-41964 | Film No.: 26829680 Mailing Address 4020 STIRRUP CREEK DRIVE SUITE 110 DURHAM NC 27703 Business Address 4020 STIRRUP CREEK DRIVE SUITE 110 DURHAM NC 27703 919-908-2422 Pelthos Therapeutics Inc. ( Issuer ) CIK : 0001919246 (see all company filings) EIN. : 863335449 | State of Incorp.: NV | Fiscal Year End: 1231 SIC : 2836 Biological Products, (No Diagnostic Substances) (CF Office: 03 Life Sciences)